To market, to market
Investors watching for new approvals and cancer, Orphan data in 2Q17
Investors are hoping that a slew of approvals and data readouts can maintain biotech’s momentum on the heels of several high-profile successes that came just before or after 1Q’s end.
Chief among those was Vertex Pharmaceuticals Inc.’s Phase III data for the combination of tezacaftor (VX-661) and Kalydeco ivacaftor in cystic fibrosis. Tezacaftor is expected to be part of a triple combination therapy that could potentially address a wider population of CF patients than those with delta F508 mutations in the cystic fibrosis transmembrane conductance regulator (CFTR)...